A Look At Insider Reactions To Syros Pharmaceuticals Inc. (SYRS)

As of Wednesday close, Syros Pharmaceuticals Inc.’s (NASDAQ:SYRS) stock was up $0.08, moving up 1.98 percent to $4.13. The average number of shares traded per day over the past five days has been 514,660 shares. 2 times new highs have been achieved over the past 5 days, with a $0.02 gain in that time frame. In the last twenty days, the average volume was 385,445, while in the previous 50 days, it was 474,116.

Since last month, SYRS stock retreated -1.20%. Shares of the company fell to $3.70 on 11/22/21, the lowest level in the past month. A 52-week high of $15.65 was reached on 01/19/21 after having rallying from a 52-week low of $3.70. Since the beginning of this year, SYRS’s stock price has dropped by -61.94% or -$6.72, and marked a new high 7 times. However, the stock has declined by -73.61% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

Syros Pharmaceuticals Inc. (SYRS) last reported insider trading activity 255 days ago on Mar 15. Olson Eric R, the Chief Scientific Officer of the company, disposed of 3,628 shares for $9.47 on Mar 15. It resulted in a $34,372 divestment by the insider. Young Richard A sold 3,750 shares at an average price of $12.05 on Feb 16. The insider now owns 321,711 shares following the transaction. On Feb 08, Director Young Richard A sold 3,750 shares at $13.04 apiece. The transaction was valued at $48,900.

Valuation Metrics

The stock’s beta is 1.85. Besides these, the trailing price-to-sales (P/S) ratio of 12.20, the price-to-book (PB) ratio of 2.44.

In the three months ended June 29, Syros Pharmaceuticals Inc.’s quick ratio stood at 5.10, while its current ratio was 5.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.38, and the total debt-to-equity ratio was 0.38. Based on annual data, SYRS earned $97.39 million in gross profit and brought in $15.09 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -62.90%. Return on equity (ROE) for the past 12 months was -78.00%. In the past year, the industry average ROE stood at -68.79.

Earnings Surprise

In Syros Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $40.07 million against cash and short-term investments of $30.16 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SYRS’s revenue rose 32.81% to $5.16 million during the quarter, while net income inched up to $5.7 million. While analysts expected Syros Pharmaceuticals Inc. to report -$0.37 quarterly earnings, the actual figure was -$0.36 per share, beating the consensus estimate by 2.70%. During the quarter, the company generated -$25.97 million in EBITDA. The liabilities of Syros Pharmaceuticals Inc. were 101.98 million at the end of its most recent quarter ended June 29, and its total debt was $65.72 million. The value of shareholders’ equity is $61.95 million.

Technical Picture

This quick technical analysis looks at Syros Pharmaceuticals Inc.’s (SYRS) price momentum. With a historical volatility rate of 42.53%, the RSI 9-day stood at 48.92% on 24 November.

With respect to its five-day moving average, the current Syros Pharmaceuticals Inc. price is up by +0.49% percent or $0.02. At present, SYRS shares trade +1.47% above its 20-day simple moving average and -21.93% percent below its 100-day simple moving average. However, the stock is currently trading approximately -21.18% below its SMA50 and -66.80% below its SMA200.

Stochastic coefficient K was 31.93% and Stochastic coefficient D was 19.75%, while ATR was 0.22. Given the Stochastic reading of 45.26% for the 14-day period, the RSI (14) reading has been calculated as 46.38%. As of today, the MACD Oscillator reading stands at -0.07, while the 14-day reading stands at -0.16.

Analyst Ratings

H.C. Wainwright upgraded its rating on Syros Pharmaceuticals Inc. (NASDAQ: SYRS) to a Buy in a note to investors on November 04, 2020. The analysts firm previously had a Neutral rating on the stock.Syros Pharmaceuticals Inc. (SYRS) has been rated Buy by analysts. According to 0 brokerage firms, SYRS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Syros Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.

What is SYRS’s price target for the next 12 months?

With a median target price of $18.00, the current consensus forecast for the stock is $9.00 – $23.00. Based on these forecasts, analysts predict Syros Pharmaceuticals Inc. (SYRS) will achieve an average price target of $17.14.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam